TY - JOUR
T1 - Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD.
AU - Bihlet, Asger R
AU - Karsdal, Morten A
AU - Bay-Jensen, Anne-Christine
AU - Read, Simon
AU - Kristensen, Jacob Hull
AU - Sand, Jannie Marie Bülow
AU - Leeming, Diana Julie
AU - Andersen, Jeppe Ragnar
AU - Lange, Peter
AU - Vestbo, Jørgen
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Despite massive investments in the development of novel treatments for heterogeneous diseases such as COPD, the resources spent have only benefited a fraction of the population treated. Personalized health care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. This review discusses past successes and failures in drug development and biomarker research in COPD, describes research in COPD phenotypes and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression, and examines the role of extracellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling that may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacologic intervention are discussed.
AB - Despite massive investments in the development of novel treatments for heterogeneous diseases such as COPD, the resources spent have only benefited a fraction of the population treated. Personalized health care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. This review discusses past successes and failures in drug development and biomarker research in COPD, describes research in COPD phenotypes and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression, and examines the role of extracellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling that may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacologic intervention are discussed.
U2 - 10.1378/chest.15-0296
DO - 10.1378/chest.15-0296
M3 - Article
C2 - 25856563
SN - 1931-3543
VL - 148
JO - Chest
JF - Chest
IS - 1
ER -